Nama's AI scorecard currently rates GRAIL Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does GRAL report earnings?

GRAIL's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$1.46.

What is the GRAL price target?

The median analyst price target from 9 analysts is $150.00, with a range of $74.00 – $180.00.

Is GRAL Shariah compliant?

Nama's AAOIFI-style screen reads GRAIL as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

GRAIL (GRAL)

Healthcare · Diagnostics Research · NASDAQ

GRAIL (GRAL) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $5.43B and a free-cash-flow yield of -6.7%. Over the most recent reported fiscal year, revenue grew 17.2%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Rising · +66.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-27.1%

How far the last close sits under the highest price of the past five years.

Market cap	$5.43B
Trailing P/E	—
Price / book	2.1
Price / sales	32.8
FCF yield	-6.7%
Dividend yield	—
Gross margin	-31.3%
Operating margin	-323.0%
Net margin	-236.9%
Revenue growth (YoY)	+17.2%
Revenue growth (3-yr annual)	+38.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

GRAL earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$1.46). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$3.00	-$1.90	+257.9%	—
Q2 2026	Aug 5, 2026	-$1.34	-$1.99	+32.7%	$44.69M
Q1 2026	May 5, 2026	-$1.37	-$1.96	+30.1%	$40.78M
Q4 2025	Feb 19, 2026	-$2.44	-$2.53	+3.6%	$43.60M

GRAL analyst price target

Median target $150.00 from 9 analysts, ranging $74.00 – $180.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live GRAL data on Nama Insights →

GRAL FAQ

Is GRAL a buy?: Nama's AI scorecard currently rates GRAIL Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does GRAL report earnings?: GRAIL's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$1.46.
What is the GRAL price target?: The median analyst price target from 9 analysts is $150.00, with a range of $74.00 – $180.00.
Is GRAL Shariah compliant?: Nama's AAOIFI-style screen reads GRAIL as Not Shariah Compliant. At least one of the three ratios or the industry test failed.